Hastina 21+7

Hastina 21+7 is a combined oral contraceptive tablet containing the synthetic progestogen drospirenone and the estrogen ethinylestradiol. Marketed in the European Union, it is taken orally and includes lactose anhydrous as an inactive ingredient. The product is classified as a hormonal contraceptive and is prescribed for the prevention of pregnancy, typically following a 21‑day active phase with a 7‑day hormone‑free interval under medical supervision and regular follow‑up.

Hastina 21+7 is indicated for women who seek reliable hormonal contraception.

- Prevention of pregnancy in women of reproductive age. - Use as part of a regular 21‑day active/7‑day placebo cycle. - May be prescribed for menstrual cycle regulation when clinically appropriate. - Can be considered for management of acne related to androgen excess in some patients. - Provides contraceptive protection immediately after the first tablet when a backup method is not required after the first 7 days.

Like other combined oral contraceptives, Hastina 21+7 may cause a range of side effects, most of which are mild and transient.

Common: - Nausea or mild stomach upset, often occurring during the first cycle. - Headache or mild migraine, which may improve after continued use. - Breast tenderness or enlargement, typically resolving after several weeks. - Spotting or breakthrough bleeding between periods, especially during the initial weeks.

Serious: - Signs of venous thromboembolism such as leg pain, swelling, redness, or sudden shortness of breath, which require immediate medical attention. - Severe allergic reaction including rash, itching, swelling of the face, lips, tongue, or throat, indicating possible anaphylaxis.

Before prescribing Hastina 21+7, clinicians evaluate several health factors to ensure safe use.

- History of blood clotting disorders, stroke, or myocardial infarction. - Current or past diagnosis of hormone‑dependent cancers such as breast or endometrial cancer. - Uncontrolled hypertension or significant cardiovascular disease. - Smoking in women over 35 years of age. - Liver disease that impairs hormone metabolism. - Pregnancy or suspected pregnancy. - Known allergy to drospirenone, ethinylestradiol, or lactose.

Hastina 21+7 can interact with other medicines, affecting its effectiveness or safety.

Avoid: - Anticoagulants such as warfarin, which may have reduced efficacy. - Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin) that lower hormone levels. - Certain antibiotics like rifampin that increase hormone metabolism. - St. John’s wort, a herbal inducer of hepatic enzymes. - HIV protease inhibitors that may increase estrogen levels.

Use with caution: - Antifungal agents (e.g., ketoconazole) that can raise hormone concentrations. - Selective serotonin reuptake inhibitors (SSRIs) that may slightly increase clot risk. - Diuretics that may affect potassium balance when combined with drospirenone.